<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637517</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_DSM265_18_01</org_study_id>
    <secondary_id>B19-227</secondary_id>
    <nct_id>NCT03637517</nct_id>
  </id_info>
  <brief_title>Malaria: Relative Bioavailability and Food Effect of DSM265</brief_title>
  <official_title>Relative Bioavailability and Effect of Food on DSM265-TPGS 34% SDD Powder in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test
      formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder
      formulation used in early clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare the relative bioavailability of oral DSM265-TPGS
      34% SDD formulation with that of a reference 25% SDD powder for suspension used in previous
      clinical trials. Another objective of the study is to evaluate the effect of food on
      bioavailability of the DSM265-TPGS 34% SDD formulation.

      The current 25% SDD powder for suspension clinical formulation is a suspension which requires
      reconstitution/administration in 240 mL sucralose based vehicle (for a 400 mg adult dose).
      This volume is too large for paediatric patients with malaria (e.g., translates into a 30 mL
      volume for 0.5-2 yr old patients); also, the dosing vehicle is not commercially viable. The
      new formulation dissolves in a smaller volume of a more common vehicle, water (40 mL for 400
      mg adult dose).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Actual">November 19, 2018</completion_date>
  <primary_completion_date type="Actual">November 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1, single-dose, open-label, randomized, parallel group design in healthy adults (males, females of non child bearing potential) in 3 groups of 14 subjects each.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>21 days</time_frame>
    <description>Maximum observed DSM265 plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC168</measure>
    <time_frame>168 hours</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to 168 hours (AUC168)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>21 days</time_frame>
    <description>AUC from time 0 until the last measurable concentration (AUCt),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>21 days</time_frame>
    <description>Time to Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>β</measure>
    <time_frame>21 days</time_frame>
    <description>Apparent terminal phase elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C168</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma concentration at 168 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>21 days</time_frame>
    <description>AUC from time 0 to infinity (AUCinf)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>DSM265-TPGS 34% SDD, 400 mg fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSM265-TPGS 34% SDD, 400 mg fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSM265 25% SDD, 400 mg fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSM265-TPGS 34% SDD, 400 mg fasted</intervention_name>
    <description>New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
    <arm_group_label>DSM265-TPGS 34% SDD, 400 mg fasted</arm_group_label>
    <other_name>DSM265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSM265-TPGS 34% SDD, 400 mg fed</intervention_name>
    <description>New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
    <arm_group_label>DSM265-TPGS 34% SDD, 400 mg fed</arm_group_label>
    <other_name>DSM265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSM265 25% SDD, 400 mg fasted</intervention_name>
    <description>Reference formulation used in early clinical trials.</description>
    <arm_group_label>DSM265 25% SDD, 400 mg fasted</arm_group_label>
    <other_name>DSM265</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Subjects or their legally authorized representative must voluntarily sign and date
             each informed consent, approved by an Independent Ethics Committee(IEC) /
             Institutional Review Board (IRB), prior to the initiation of any screening or
             study-specific procedures.

          2. Male or female between 18 and 55 years of age inclusive at the time of screening.

          3. Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the tenths decimal.
             BMI is calculated as weight in kg divided by the square of height measured in meters.

          4. Females must be of Non-Childbearing Potential as defined below

             Females do not need to use birth control during or following study drug treatment if
             considered of non-childbearing potential due to meeting any of the following criteria:

               -  Postmenopausal, age ≤ 55 years with no menses for 12 or more months without an
                  alternative medical cause AND an follicle stimulating hormone (FSH) level &gt; 40
                  IU/L.

               -  Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy,
                  or hysterectomy).

          5. Female who is not pregnant, breastfeeding, or considering becoming pregnant during the
             study or for approximately 120 days after the last dose of study drug.

          6. Male subjects who are sexually active with a female partner of childbearing potential,
             must agree to use condoms, even if the male subject has undergone a successful
             vasectomy, from Study Day 1 through 120 days after the last dose of study drug. His
             female partner(s) must also use at least one of the following methods of birth
             control:

               -  Combined (oestrogen and progestogen containing) hormonal birth control (oral,
                  intravaginal, injectable, transdermal) associated with inhibition of ovulation
                  initiated at least 30 days prior to study Baseline Day 1.

               -  Progestogen-only hormonal birth control (oral, injectable, implantable)
                  associated with inhibition of ovulation initiated at least 30 days prior to study
                  Baseline Day 1.

               -  Bilateral tubal occlusion/ligation.

               -  Intrauterine device (IUD).

               -  Intrauterine hormone-releasing system (IUS).

          7. Male who is not considering fathering a child or donating sperm during the study or
             for approximately 120 days after the last dose of study drug.

          8. Laboratory values meet the following criteria:

               -  Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ the upper
                  limit of normal (ULN) at the Screening Visit and upon initial confinement.

               -  Negative test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis
                  B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (Ab) and human
                  immunodeficiency virus (HIV) at screening visit.

               -  Negative screen for drugs of abuse, alcohol or cotinine at screening and upon
                  initial confinement.

               -  For non-postmenopausal female subjects, a negative urine pregnancy test at the
                  screening visit and a negative serum pregnancy test upon initial confinement and
                  prior to the first dose of study drug.

               -  No other laboratory results that the investigator determines are clinically
                  significant.

               -  Platelets greater than or equal to the lower limit of normal.

          9. No clinically significant ECG abnormalities including

               -  No evidence of 2nd or 3rd degree AV block at screening visit and upon initial
                  confinement.

               -  QT interval corrected for heart rate (QTc) using Fridericia's correction formula
                  (QTcF) is ≤ 430 msec (males) or ≤ 450 msec (females) at screening visit and upon
                  initial confinement.

         10. A condition of general good health, based upon the results of a medical history,
             physical examination, vital signs, laboratory profile and a 12-lead ECG.

         11. No history of: epilepsy, any clinically significant cardiac, respiratory (except mild
             asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric
             disease or disorder, or any uncontrolled medical illness.

         12. No history of any clinically significant sensitivity or allergy to any medication or
             food.

         13. No history of or active medical condition(s) or surgical procedure(s) that might
             affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac
             disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy
             for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection].

         14. No evidence of dysplasia or history of malignancy (including lymphoma and leukemia)
             other than successfully treated non-metastatic cutaneous squamous cell, basal cell
             carcinoma or localized carcinoma in situ of the cervix.

         15. No history of any clinically significant illness/infection/major febrile illness,
             hospitalization, or any surgical procedure within 30 days prior to the first dose of
             study drug.

         16. Has not donated blood (including plasmapheresis), lost ≥ 550 mL blood volume, or
             received a transfusion of any blood product within 8 weeks prior to study drug
             administration.

         17. No consumption of alcohol, grapefruit products, Seville oranges, starfruit products or
             quinine/tonic water within the 72-hour period prior to study drug administration.

         18. No use of tobacco or nicotine-containing products within 180 days prior to the first
             dose of study drug.

         19. No history of clinically significant (per Investigator's judgment) drug or alcohol
             abuse within the last 6 months.

         20. Is not currently enrolled in another interventional clinical study.

         21. Has not been previously enrolled in this study.

         22. In the opinion of the investigator, this subject is a suitable candidate for
             enrollment in the study.

         23. Subjects must not have been treated with any investigational drug within 30 days or 5
             half-lives of the drug (whichever is longer) prior to the first dose of study drug.

         24. Subject must not have received any live vaccine within 4 weeks prior to the first dose
             of study drug, or expected need of live vaccination during study participation
             including at least 4 weeks after the last dose of study drug.

         25. Subject must not require any over-the-counter and/or prescription medication, vitamins
             and/or herbal supplements, with the exception of contraceptives or hormonal
             replacement therapies for females, on a regular basis.

         26. Subject must not use any medications within the 2-week period prior to study drug
             administration.

         27. Receipt of any drug by injection within 30 days or within a period defined by 5
             half-lives, whichever is longer, prior to study drug administration.

         28. No use of known inhibitors (e.g., ketoconazole) or inducers (e.g., carbamazepine) of
             cytochrome P450 3A (CYP3A) within 1 month prior to study drug administration.

         29. No exposure to DSM265 within the past 90 days prior to first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Moehrle, Ass Prof</last_name>
    <role>Study Director</role>
    <affiliation>Medicines for Malaria Venture</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AbbVie Clinical Pharmacology Research Unit (ACPRU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AbbVie Clinical Pharmacology Research Unit (ACPRU)</name>
      <address>
        <city>Grayslake</city>
        <state>Illinois</state>
        <zip>60030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <results_first_submitted>February 25, 2020</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2020</results_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03637517/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03637517/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical Pharmacology phase 1 unit.</recruitment_details>
      <pre_assignment_details>30 day screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DSM265 25% SDD, 400 mg Fasted</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
        </group>
        <group group_id="P2">
          <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
        </group>
        <group group_id="P3">
          <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DSM265 25% SDD, 400 mg Fasted</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
        </group>
        <group group_id="B2">
          <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
        </group>
        <group group_id="B3">
          <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.9" spread="10.78"/>
                    <measurement group_id="B2" value="36.1" spread="9.23"/>
                    <measurement group_id="B3" value="38.6" spread="10.58"/>
                    <measurement group_id="B4" value="37.6" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum observed DSM265 plasma concentration</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum observed DSM265 plasma concentration</description>
          <units>NG/ML</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15300" spread="27"/>
                    <measurement group_id="O2" value="14200" spread="28"/>
                    <measurement group_id="O3" value="11200" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>2 comparisons performed: Reg. B vs. Reg. A, &amp; Reg.C vs. Reg. B. Bioavailability of each test reg. relative to that of each reference reg. assessed via 90% CI. CI obtained by taking the antilog of the upper and lower limits of CI for the difference of the least squares means on the log scale within the ANOVA framework model. Bioequivalence between a test reg. and the reference reg. is concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.4847</p_value>
            <method>ANOVA</method>
            <param_type>Least Squares Means Log scale</param_type>
            <param_value>0.926</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.771</ci_lower_limit>
            <ci_upper_limit>1.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>2 comparisons performed: Reg. B vs. Reg. A, &amp; Reg.C vs. Reg. B. Bioavailability of each test reg. relative to that of each reference reg. assessed via 90% CI. CI obtained by taking the antilog of the upper and lower limits of CI for the difference of the least squares means on the log scale within the ANOVA framework model. Bioequivalence between a test reg. and the reference reg. is concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.0370</p_value>
            <method>ANOVA</method>
            <param_type>Least Squares Means Log scale</param_type>
            <param_value>0.790</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.658</ci_lower_limit>
            <ci_upper_limit>0.950</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC168</title>
        <description>Area under the plasma concentration-time curve from time 0 to 168 hours (AUC168)</description>
        <time_frame>168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC168</title>
          <description>Area under the plasma concentration-time curve from time 0 to 168 hours (AUC168)</description>
          <units>NG*H/ML</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100000" spread="14"/>
                    <measurement group_id="O2" value="987000" spread="17"/>
                    <measurement group_id="O3" value="1160000" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability of each test reg. relative to each reference reg will be assessed via 90% CI obtained from the analyses of the natural logs of Cmax and AUC. These CI are obtained by taking the antilog of the upper &amp; lower CI for the difference of the least squares means on the log scale within the ANOVA model. Bioequivalence between a test reg and the respective reference reg will be concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.1135</p_value>
            <method>ANOVA</method>
            <param_type>Sum of squares</param_type>
            <param_value>0.899</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.805</ci_lower_limit>
            <ci_upper_limit>1.004</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability of each test reg. relative to each reference reg will be assessed via 90% CI obtained from the analyses of the natural logs of Cmax and AUC. These CI are obtained by taking the antilog of the upper &amp; lower CI for the difference of the least squares means on the log scale within the ANOVA model. Bioequivalence between a test reg and the respective reference reg will be concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.0192</p_value>
            <method>ANOVA</method>
            <param_type>Sum of squares</param_type>
            <param_value>1.175</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.051</ci_lower_limit>
            <ci_upper_limit>1.312</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCt</title>
        <description>AUC from time 0 until the last measurable concentration (AUCt),</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt</title>
          <description>AUC from time 0 until the last measurable concentration (AUCt),</description>
          <units>NG*H/ML</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1750000" spread="20"/>
                    <measurement group_id="O2" value="1570000" spread="19"/>
                    <measurement group_id="O3" value="1840000" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability of each test reg. relative to each reference reg will be assessed via 90% CI obtained from the analyses of the natural logs of Cmax and AUC. These CI are obtained by taking the antilog of the upper &amp; lower CI for the difference of the least squares means on the log scale within the ANOVA model. Bioequivalence between a test reg and the respective reference reg will be concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.1759</p_value>
            <method>ANOVA</method>
            <param_type>Sum of squares</param_type>
            <param_value>0.898</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.787</ci_lower_limit>
            <ci_upper_limit>1.024</ci_upper_limit>
            <estimate_desc>Regimen B to A</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability of each test reg. relative to each reference reg will be assessed via 90% CI obtained from the analyses of the natural logs of Cmax and AUC. These CI are obtained by taking the antilog of the upper &amp; lower CI for the difference of the least squares means on the log scale within the ANOVA model. Bioequivalence between a test reg and the respective reference reg will be concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.0496</p_value>
            <method>ANOVA</method>
            <param_type>Sum of squares</param_type>
            <param_value>1.172</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.027</ci_lower_limit>
            <ci_upper_limit>1.338</ci_upper_limit>
            <estimate_desc>Regimen C to B</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to Cmax.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to Cmax.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.4"/>
                    <measurement group_id="O2" value="2.1" spread="0.9"/>
                    <measurement group_id="O3" value="11.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability of each test reg. relative to each reference reg will be assessed via 90% CI obtained from the analyses of the natural logs of Cmax and AUC. These CI are obtained by taking the antilog of the upper &amp; lower CI for the difference of the least squares means on the log scale within the ANOVA model. Bioequivalence between a test reg and the respective reference reg will be concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>-0.2857</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.866979</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4313</ci_lower_limit>
            <ci_upper_limit>2.8599</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability of each test reg. relative to each reference reg will be assessed via 90% CI obtained from the analyses of the natural logs of Cmax and AUC. These CI are obtained by taking the antilog of the upper &amp; lower CI for the difference of the least squares means on the log scale within the ANOVA model. Bioequivalence between a test reg and the respective reference reg will be concluded if the 90% CI from the analyses of the natural log of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>9.3571</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.866979</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.2115</ci_lower_limit>
            <ci_upper_limit>12.5028</ci_upper_limit>
            <estimate_desc>Regimen C to B</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>β</title>
        <description>Apparent terminal phase elimination rate constant</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>β</title>
          <description>Apparent terminal phase elimination rate constant</description>
          <units>1/H</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00556" spread="0.00189"/>
                    <measurement group_id="O2" value="0.00531" spread="0.00154"/>
                    <measurement group_id="O3" value="0.00595" spread="0.00231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C168</title>
        <description>Plasma concentration at 168 hours</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>C168</title>
          <description>Plasma concentration at 168 hours</description>
          <units>NG/ML</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4090" spread="25"/>
                    <measurement group_id="O2" value="3540" spread="25"/>
                    <measurement group_id="O3" value="4200" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(ANOVA) will be performed for Tmax, the terminal phase elimination rate constant β, and the natural logarithms of Cmax, AUCt, AUC168, AUCinf, and C168. The model will include the effects for regimen. For the tests on regimen effects, the denominator sum of squares will be the residual sum of squares for error. Within the ANOVA modeling framework, the test regimen will be compared to the respective reference regimen by a test with a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between a test regimen and the respective reference regimen will be concluded if the 90% confidence intervals from the analyses of the natural logarithms of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.1745</p_value>
            <method>ANOVA</method>
            <param_type>Sum of squares</param_type>
            <param_value>0.866</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.727</ci_lower_limit>
            <ci_upper_limit>1.032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between a test regimen and the respective reference regimen will be concluded if the 90% confidence intervals from the analyses of the natural logarithms of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.1105</p_value>
            <p_value_desc>For tests on regimen effects, the denominator sum of squares is the residual sum of squares for error. Within the ANOVA modeling framework, the test regimen is compared to the respective reference regimen by a test with a significance level of 0.05.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Sum of squares</param_type>
            <param_value>1.185</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.995</ci_lower_limit>
            <ci_upper_limit>1.411</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCinf</title>
        <description>AUC from time 0 to infinity (AUCinf)</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSM265 25% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
          </group>
          <group group_id="O2">
            <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
          </group>
          <group group_id="O3">
            <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
            <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf</title>
          <description>AUC from time 0 to infinity (AUCinf)</description>
          <units>NG*H/ML</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1960000" spread="29"/>
                    <measurement group_id="O2" value="1760000" spread="26"/>
                    <measurement group_id="O3" value="2040000" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between a test regimen and the respective reference regimen will be concluded if the 90% confidence intervals from the analyses of the natural logarithms of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.3100</p_value>
            <method>ANOVA</method>
            <param_type>LEAST SQUARES MEANS FOR LOGARITHMS.</param_type>
            <param_value>0.901</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.759</ci_lower_limit>
            <ci_upper_limit>1.069</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between a test regimen and the respective reference regimen will be concluded if the 90% confidence intervals from the analyses of the natural logarithms of Cmax and AUC are within the 0.80 to 1.25 range.</non_inferiority_desc>
            <p_value>0.1619</p_value>
            <method>ANOVA</method>
            <param_type>LEAST SQUARES MEANS FOR LOGARITHMS.</param_type>
            <param_value>1.156</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.974</ci_lower_limit>
            <ci_upper_limit>1.371</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events reported from the time of study drug administration until 30 days or 5 half-lives after discontinuation of study drug administration will be collected, whether solicited or spontaneously reported by the subject. In addition, serious adverse events and protocol-related non-serious adverse events will be collected from the time the subject signs the study-specific informed consent.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DSM265 25% SDD, 400 mg Fasted</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
DSM265 25% SDD, 400 mg fasted: Reference formulation used in early clinical trials.</description>
        </group>
        <group group_id="E2">
          <title>DSM265-TPGS 34% SDD, 400 mg Fasted</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fasted: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.</description>
        </group>
        <group group_id="E3">
          <title>DSM265-TPGS 34% SDD, 400 mg Fed</title>
          <description>Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
DSM265-TPGS 34% SDD, 400 mg fed: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Chalon, MD</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0369</phone>
      <email>chalons@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

